Wall Street brokerages forecast that Intellia Therapeutics Inc (NASDAQ:NTLA) will post ($0.43) earnings per share for the current quarter, Zacks Investment Research reports. Four analysts have made estimates for Intellia Therapeutics’ earnings. The highest EPS estimate is ($0.28) and the lowest is ($0.49). Intellia Therapeutics posted earnings of ($0.31) per share in the same quarter last year, which would indicate a negative year over year growth rate of 38.7%. The company is scheduled to announce its next earnings report on Tuesday, March 13th.
On average, analysts expect that Intellia Therapeutics will report full-year earnings of ($1.68) per share for the current year, with EPS estimates ranging from ($1.74) to ($1.53). For the next year, analysts anticipate that the firm will report earnings of ($1.94) per share, with EPS estimates ranging from ($2.34) to ($1.52). Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Intellia Therapeutics.
Intellia Therapeutics (NASDAQ:NTLA) last issued its earnings results on Tuesday, October 31st. The company reported ($0.44) EPS for the quarter, beating analysts’ consensus estimates of ($0.50) by $0.06. Intellia Therapeutics had a negative return on equity of 28.01% and a negative net margin of 215.92%. The business had revenue of $7.30 million during the quarter, compared to analyst estimates of $5.83 million. During the same period in the previous year, the company posted ($0.22) EPS. The firm’s revenue was up 49.0% compared to the same quarter last year.
In other news, CEO Nessan Bermingham sold 111,500 shares of the business’s stock in a transaction that occurred on Wednesday, December 6th. The stock was sold at an average price of $20.34, for a total value of $2,267,910.00. Following the transaction, the chief executive officer now owns 696,000 shares in the company, valued at approximately $14,156,640. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, major shareholder Institutes For Biomed Novartis sold 1,523,000 shares of the business’s stock in a transaction that occurred on Tuesday, December 12th. The stock was sold at an average price of $18.30, for a total value of $27,870,900.00. The disclosure for this sale can be found here. Insiders have sold a total of 1,971,283 shares of company stock valued at $37,137,161 over the last three months. Corporate insiders own 12.80% of the company’s stock.
Hedge funds and other institutional investors have recently made changes to their positions in the company. Schwab Charles Investment Management Inc. lifted its stake in Intellia Therapeutics by 58.6% in the second quarter. Schwab Charles Investment Management Inc. now owns 42,674 shares of the company’s stock valued at $683,000 after purchasing an additional 15,771 shares during the last quarter. Rhumbline Advisers purchased a new position in Intellia Therapeutics in the second quarter valued at approximately $275,000. State of Wisconsin Investment Board purchased a new position in Intellia Therapeutics in the second quarter valued at approximately $160,000. SG Americas Securities LLC purchased a new position in Intellia Therapeutics in the second quarter valued at approximately $101,000. Finally, Bank of New York Mellon Corp lifted its stake in Intellia Therapeutics by 73.0% in the second quarter. Bank of New York Mellon Corp now owns 54,802 shares of the company’s stock valued at $876,000 after purchasing an additional 23,126 shares during the last quarter. Hedge funds and other institutional investors own 48.95% of the company’s stock.
Shares of Intellia Therapeutics (NASDAQ NTLA) opened at $20.16 on Thursday. Intellia Therapeutics has a 12-month low of $10.83 and a 12-month high of $33.34. The company has a market capitalization of $853.48 and a PE ratio of -13.01.
COPYRIGHT VIOLATION NOTICE: “-$0.43 Earnings Per Share Expected for Intellia Therapeutics Inc (NTLA) This Quarter” was first posted by BBNS and is owned by of BBNS. If you are viewing this article on another website, it was copied illegally and reposted in violation of United States and international copyright laws. The correct version of this article can be accessed at https://baseballnewssource.com/markets/0-43-earnings-per-share-expected-for-intellia-therapeutics-inc-ntla-this-quarter/1824468.html.
About Intellia Therapeutics
Intellia Therapeutics, Inc is a genome editing company. The Company is focused on developing therapeutics utilizing a biological tool known as CRISPR/Cas9. The CRISPR/Cas9 genome editing system includes two components: the Cas9 protein and the guide RNA sequence. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.